Top

Published in:

Open Access 01-12-2017 | Study protocol

Testing the effectiveness of a motivational interviewing-based brief intervention for substance use as an adjunct to usual care in community-based AIDS service organizations: study protocol for a multisite randomized controlled trial

Authors: Bryan R. Garner, Heather J. Gotham, Stephen J. Tueller, Elizabeth L. Ball, David Kaiser, Patricia Stilen, Kathryn Speck, Denna Vandersloot, Traci R. Rieckmann, Michael Chaple, Erika G. Martin, Steve Martino

Published in: Addiction Science & Clinical Practice | Issue 1/2017

Abstract

Background

In 2010, the first comprehensive National HIV/AIDS Strategy for the United States was released and included three goals: (1) reducing the number of people who become infected with HIV, (2) increasing access to care and improving health outcomes for people living with HIV, and (3) reducing HIV-related health disparities and health inequities. In 2013, as part of its effort to help address the National HIV/AIDS Strategy, the National Institute on Drug Abuse (NIDA) funded a type 2 effectiveness-implementation hybrid trial titled the Substance Abuse Treatment to HIV Care (SAT2HIV) Project. Aim 1 of the SAT2HIV Project tests the effectiveness of a motivational interviewing-based brief intervention (MIBI) for substance use as an adjunct to usual care within AIDS Service Organizations (ASOs) as part of its MIBI Experiment. Aim 2 of the SAT2HIV Project tests the effectiveness of implementation and sustainment facilitation (ISF) as an adjunct to the Addiction Technology Transfer Center (ATTC) model for training staff in motivational interviewing as part of its ISF Experiment. The current paper describes the study protocol for the MIBI Experiment.

Methods

As part of a multisite randomized controlled trial, individuals with comorbid HIV/AIDS and problematic substance use are randomized to receive either the ASOs’ usual care (control condition) or usual care plus a MIBI for substance use (experimental condition) delivered by trained ASO case-management staff. Primary outcome measures are reductions in days of primary substance use, number of substance-related problems, times engaging in risky behaviors, days of non-adherence to HIV medications, and increases in substance use treatment. As part of this paper, we describe the trial protocol in accordance with the Standard Protocol Items: Recommendations for Interventional Trials guidelines.

Discussion

If successfully able to implement MIBI as an effective adjunct to usual care, the current trial may have a significant impact on increasing the capacity of ASOs to address problematic substance use among individuals living with HIV/AIDS. Reducing the prevalence of problematic substance use among individuals living with HIV/AIDS within the United States may lead to significant improvements on key performance measures (i.e., the HIV Care Continuum and the 90-90-90 target).

Trial registration ClinicalTrials.gov: NCT02495402

Available only for authorised users

White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Updated to 2020. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf (2015). Accessed 28 Aug 2015.

Centers for Disease Control and Prevention. New HIV infections in the United States. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/new-hiv-infections-508.pdf (2016). Accessed 10 Jan 2017.

Centers for Disease Control and Prevention. HIV cost-effectiveness. http://www.cdc.gov/hiv/prevention/ongoing/costeffectiveness/ (2013). Accessed 28 Aug 2015.

Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, Skarbinski J, Higa DH, Prejean J, Frazier EL, et al. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV–United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7.PubMedPubMedCentral

Insight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fatkenheuer G, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. https://doi.org/10.1056/NEJMoa1506816.CrossRef

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. https://doi.org/10.1056/NEJMoa1105243.CrossRefPubMedPubMedCentral

Centers for Disease Control and Prevention. HIV Surveillance Report. Volume 25. http://www.cdc.gov/hiv/library/reports/surveillance/ (2013). Accessed 24 Aug 2016.

Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and dependent areas, 2015. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf. Accessed 10 Jan 2017.

U.S. Department of Health and Human Services. Part 1. Overview information. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-14-011.html (n.d.). Accessed 10 Jan 2017.

10.

Rhode Island Hospital. Implementation to motivate physician response to opioid dependence in HIV setting In: NIH RePORTER [Internet]. Washington, DC: NIH RePORTER. https://projectreporter.nih.gov/project_info_description.cfm?aid=8768926&icde=32527944&ddparam=&ddvalue=&ddsub=&cr=17&csb=default&cs=ASC&pball=NLMIdentifier:1R01DA038082-01. Accessed 10 Jan 2017.

11.

Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–26. https://doi.org/10.1097/MLR.0b013e3182408812.CrossRefPubMedPubMedCentral

12.

Research Triangle Institute. Substance abuse treatment to HIV care (SAT2HIV) In: NIH RePORTER [Internet]. Washington, DC: NIH RePORTER. Available from: https://projectreporter.nih.gov/project_info_description.cfm?aid=8883478&icde=32528000&ddparam=&ddvalue=&ddsub=&cr=8&csb=default&cs=ASC&pball=NLMIdentifier:5R01DA038146-03. Accessed 10 Jan 2017.

13.

Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. https://doi.org/10.7326/0003-4819-158-3-201302050-00583.CrossRefPubMedPubMedCentral

14.

Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https://doi.org/10.1136/bmj.e7586.CrossRefPubMedPubMedCentral

15.

Garner BR, Zehner M, Roosa, MR, Martino, S, Gotham HJ, Ball, EL, et al. Testing the implementation and sustainment facilitation (ISF) strategy as an effective adjunct to the Addiction Technology Transfer Center (ATTC) strategy: study protocol for a cluster randomized trial. Addict Sci Clin Pract. 2017. https://doi.org/10.1186/s13722-017-0096-7.

16.

Saitz R, Alford DP, Bernstein J, Cheng DM, Samet J, Palfai T. Screening and brief intervention for unhealthy drug use in primary care settings: randomized clinical trials are needed. J Addict Med. 2010;4(3):123–30. https://doi.org/10.1097/ADM.0b013e3181db6b67.CrossRefPubMedPubMedCentral

17.

Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–95. https://doi.org/10.1016/j.drugalcdep.2008.08.003.CrossRefPubMed

18.

Humeniuk R, Ali R, Babor T, Souza-Formigoni ML, de Lacerda RB, Ling W, McRee B, Newcombe D, Pal H, Poznyak V, et al. A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction. 2012;107(5):957–66. https://doi.org/10.1111/j.1360-0443.2011.03740.x.CrossRefPubMed

19.

Aharonovich E, Greenstein E, O’Leary A, Johnston B, Seol SG, Hasin DS. HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients—a pilot study. AIDS Care. 2012;24(12):1461–9. https://doi.org/10.1080/09540121.2012.663882.CrossRefPubMedPubMedCentral

20.

Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005;77(1):49–59. https://doi.org/10.1016/j.drugalcdep.2004.07.006.CrossRefPubMed

21.

Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, group C, Pragmatic Trials in Healthcare g. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:2390. https://doi.org/10.1136/bmj.a2390.CrossRef

22.

Roy-Byrne P, Bumgardner K, Krupski A, Dunn C, Ries R, Donovan D, West II, Maynard C, Atkins DC, Graves MC, et al. Brief intervention for problem drug use in safety-net primary care settings: a randomized clinical trial. JAMA. 2014;312(5):492–501. https://doi.org/10.1001/jama.2014.7860.CrossRefPubMedPubMedCentral

23.

Saitz R, Palfai TP, Cheng DM, Alford DP, Bernstein JA, Lloyd-Travaglini CA, Meli SM, Chaisson CE, Samet JH. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014;312(5):502–13. https://doi.org/10.1001/jama.2014.7862.CrossRefPubMedPubMedCentral

24.

Aharonovich E, Sarvet A, Stohl M, DesJarlais D, Tross S, Hurst T, Urbina A, Hasin D. Reducing non-injection drug use in HIV primary care: a randomized trial of brief motivational interviewing, with and without HealthCall, a technology-based enhancement. J Subst Abuse Treat. 2017;74:71–9. https://doi.org/10.1016/j.jsat.2016.12.009.CrossRefPubMed

25.

Korthuis PT, Fiellin DA, McGinnis KA, Skanderson M, Justice AC, Gordon AJ, Doebler DA, Asch SM, Fiellin LE, Bryant K, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8. https://doi.org/10.1097/QAI.0b013e31826741aa.CrossRefPubMedPubMedCentral

26.

Korthuis PT, Saha S, Chander G, McCarty D, Moore RD, Cohn JA, Sharp VL, Beach MC. Substance use and the quality of patient-provider communication in HIV clinics. AIDS Behav. 2011;15(4):832–41. https://doi.org/10.1007/s10461-010-9779-8.CrossRefPubMedPubMedCentral

27.

Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242–57. https://doi.org/10.1111/j.1360-0443.2008.02269.x.CrossRefPubMed

28.

Friedman MS, Marshal MP, Stall R, Kidder DP, Henny KD, Courtenay-Quirk C, Wolitski RJ, Aidala A, Royal S, Holtgrave DR. Associations between substance use, sexual risk taking and HIV treatment adherence among homeless people living with HIV. AIDS Care. 2009;21(6):692–700. https://doi.org/10.1080/09540120802513709.CrossRefPubMed

29.

Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202. https://doi.org/10.1097/QAI.0b013e3181b18b6e.CrossRefPubMedPubMedCentral

30.

Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93. https://doi.org/10.1016/j.drugalcdep.2010.06.014.CrossRefPubMedPubMedCentral

31.

Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.CrossRefPubMed

32.

Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.CrossRefPubMedPubMedCentral

33.

King WD, Larkins S, Hucks-Ortiz C, Wang PC, Gorbach PM, Veniegas R, Shoptaw S. Factors associated with HIV viral load in a respondent driven sample in Los Angeles. AIDS Behav. 2009;13(1):145–53. https://doi.org/10.1007/s10461-007-9337-1.CrossRefPubMed

34.

Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, Heffelfinger JD. Clinical and behavioral characteristics of adults receiving medical care for HIV infection—Medical Monitoring Project, United States, 2007. MMWR Surveill Summ. 2011;60(11):1–20.PubMed

35.

Motivational Interviewing Network of Trainers. Welcome to the motivational interviewing page! http://www.motivationalinterviewing.org/ (2016). Accessed 10 Jan 2017.

36.

Martino S, Ball SA, Nich C, Frankforter TL, Carroll KM. Community program therapist adherence and competence in motivational enhancement therapy. Drug Alcohol Depend. 2008;96(1–2):37–48. https://doi.org/10.1016/j.drugalcdep.2008.01.020.CrossRefPubMedPubMedCentral

37.

McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199–213.CrossRefPubMed

38.

NIH Research Portfolio Online Reporting Tools (RePORT). Project start: screening to augment referral to treatment. (Project Number: 1R01DA027194-01A2). https://projectreporter.nih.gov/project_info_description.cfm?aid=8016963&icde=34207467 (2010). Accessed May 10 2017.

39.

Raudenbush SW, et al. Optimal design software for multi-level and longitudinal research (Version 3.01) [Software]. 2011.

40.

Sealed Envelope Ltd. Randomisation and online databases for clinical trials. https://www.sealedenvelope.com/ (2001-2017). Accessed 10 Jan 2017.

41.

Research Triangle Institute. RTI International Office of Research Protection. Research with human subjects. Accessed 10 Jan 2017.

42.

U.S. House of Representatives. Health Insurance Portability and Accountability Act of 1996. In: Book Health Insurance Portability and Accountability Act of 1996 (Editor ed.^eds.). pp. 1–349. City: U.S. Government Printing Office; 1996:1–349.

43.

Voxco. Voxco Survey Software. New York, NY: Voxco; 2016.

44.

National Institute of Standards and Technology, Information Technology Library. FIPS Publications (2007). Accessed 24 Jan 2017.

45.

Little RJA, Rubin DB. The analysis of social science data with missing values. Sociol Methods Res. 1989;18(2–3):292–326. https://doi.org/10.1177/0049124189018002004.CrossRef

46.

Figueredo AJ, McKnight PE, McKnight KM, Sidani S. Multivariate modeling of missing data within and across assessment waves. Addiction. 2000;95(Suppl 3):S361–80.CrossRefPubMed

47.

Raudenbush SW, Bryk AS, Congdon R. HLM 7.01 for Windows [Computer software]. Stokie, IL: Scientific Software International, Inc.; 2013.

48.

Neyman J, Pearson ES. On the use and interpretation of certain test criteria for purposes of statistical inference. Biometrika. 1928;20A:175–240.

49.

Garner BR, Hunter BD. Examining the temporal relationship between psychological climate, work attitude, and staff turnover. J Subst Abuse Treat. 2013;44(2):193–200. https://doi.org/10.1016/j.jsat.2012.05.002.CrossRefPubMed

50.

Garner BR, Hunter BD, Godley SH, Godley MD. Training and retaining staff to competently deliver an evidence-based practice: the role of staff attributes and perceptions of organizational functioning. J Subst Abuse Treat. 2012;42(2):191–200. https://doi.org/10.1016/j.jsat.2011.10.016.CrossRefPubMed

51.

Garner BR, Hunter BD, Modisette KC, Ihnes PC, Godley SH. Treatment staff turnover in organizations implementing evidence-based practices: turnover rates and their association with client outcomes. J Subst Abuse Treat. 2012;42(2):134–42. https://doi.org/10.1016/j.jsat.2011.10.015.CrossRefPubMed

52.

Garner BR, Funk RR, Hunter BD. The relationship between clinician turnover and adolescent treatment outcomes: an examination from the client perspective. J Subst Abuse Treat. 2013;44(4):444–8. https://doi.org/10.1016/j.jsat.2012.09.004.CrossRefPubMed

53.

Olmstead T, Carroll KM, Canning-Ball M, Martino S. Cost and cost-effectiveness of three strategies for training clinicians in motivational interviewing. Drug Alcohol Depend. 2011;116(1–3):195–202. https://doi.org/10.1016/j.drugalcdep.2010.12.015.CrossRefPubMedPubMedCentral

54.

Martino S, Paris M Jr, Anez L, Nich C, Canning-Ball M, Hunkele K, Olmstead TA, Carroll KM. The effectiveness and cost of clinical supervision for motivational interviewing: a randomized controlled trial. J Subst Abuse Treat. 2016;68:11–23. https://doi.org/10.1016/j.jsat.2016.04.005.CrossRefPubMedPubMedCentral

55.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.CrossRef

56.

UNAIDS. 90-90-90. An Ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf (2014). Accessed 24 Jan 2017.

57.

Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. https://doi.org/10.1093/cid/ciq243.CrossRefPubMedPubMedCentral

58.

Centers for Disease Control and Prevention. Understanding the HIV Care Continuim. http://www.cdc.gov/hiv/pdf/DHAP_Continuum.pdf (2016). Accessed 25 Jan 2017.

59.

AIDS.gov. HIV/AIDS Care Continuum. https://www.aids.gov/federal-resources/policies/care-continuum/ (2015). Accessed 11 Jan 2017.

60.

Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87. https://doi.org/10.1016/s0140-6736(10)60829-x.CrossRefPubMedPubMedCentral

61.

Gwadz M, de Guzman R, Freeman R, Kutnick A, Silverman E, Leonard NR, Ritchie AS, Munoz-Plaza C, Salomon N, Wolfe H, et al. Exploring how substance use impedes engagement along the HIV care continuum: a qualitative study. Front Public Health. 2016;4:62. https://doi.org/10.3389/fpubh.2016.00062.PubMedPubMedCentral

62.

Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11. https://doi.org/10.1097/PSY.0b013e31816aa0cc.CrossRefPubMedPubMedCentral

63.

Palepu A, Tyndall M, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32(5):522–6.CrossRefPubMed

64.

Bing EG, Burnam A, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8. https://doi.org/10.1001/archpsyc.58.8.721.CrossRefPubMed

65.

Institute of Medicine. Bridging the gap between practice and research: forging partnerships with community-based drug and alcohol treatment. Washington, DC: National Academy Press; 1998.

66.

Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.

67.

Hogan MF. The President’s New Freedom Commission: recommendations to transform mental health care in America. Psychiatr Serv. 2003;54(11):1467–74.CrossRefPubMed

68.

Institute of Medicine. Improving the quality of health care for mental and substance-use conditions: quality chasm series. Washington, DC: National Academy Press; 2006.

69.

Garner BR. Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review. J Subst Abuse Treat. 2009;36(4):376–99. https://doi.org/10.1016/j.jsat.2008.08.004.CrossRefPubMed

Title: Testing the effectiveness of a motivational interviewing-based brief intervention for substance use as an adjunct to usual care in community-based AIDS service organizations: study protocol for a multisite randomized controlled trial
Authors: Bryan R. Garner
Heather J. Gotham
Stephen J. Tueller
Elizabeth L. Ball
David Kaiser
Patricia Stilen
Kathryn Speck
Denna Vandersloot
Traci R. Rieckmann
Michael Chaple
Erika G. Martin
Steve Martino
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Addiction Science & Clinical Practice / Issue 1/2017
Electronic ISSN: 1940-0640
DOI: https://doi.org/10.1186/s13722-017-0095-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Testing the effectiveness of a motivational interviewing-based brief intervention for substance use as an adjunct to usual care in community-based AIDS service organizations: study protocol for a multisite randomized controlled trial

Abstract

Background

Methods

Discussion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Discussion

Please log in to get access to this content

Other articles of this Issue 1/2017

Comparison of DSM-IV and DSM-5 criteria for alcohol use disorders in VA primary care patients with frequent heavy drinking enrolled in a trial

Public sector low threshold office-based buprenorphine treatment: outcomes at year 7

The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy

Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol

Rethinking alcohol interventions in health care: a thematic meeting of the International Network on Brief Interventions for Alcohol & Other Drugs (INEBRIA)

Prevalence and factors associated with use of khat: a survey of patients entering HIV treatment programs in Ethiopia